Efficacy and safety of seven Chinese patent medicines combined with conventional triple/quadruple therapy for <i>Helicobacter pylori</i>-positive peptic ulcers: a systematic review and network meta-analysis.

Abstract

To compare the efficacy and safety of seven Chinese patent medicines (CPMs) combined with conventional triple/quadruple therapy (T/Q) for <i>Helicobacter pylori</i>-positive peptic ulcers. A systematic review and network meta-analysis. China National Knowledge Infrastructure, VIP database, Wanfang database, ScienceDirect, EBSCO, EMBASE, Web of Science, Cochrane Library and PubMed were searched through 1 June 2022. Randomised controlled trials (RCTs) testing CPMs combined with T/Q for <i>H. pylori</i>-positive peptic ulcers were included. The CPMs included Anweiyang capsule, Jianweiyuyang tablets/capsule/granule, Jinghuaweikang capsule, Kangfuxin liquid, Puyuanhewei capsule, Weifuchun tablets/capsule and Weisu granule. At least one of the following outcome indicators was recorded: complete ulcer healing rate (CUHR), effective rate (ER), <i>H. pylori</i> eradication rate (<i>HP</i>ER), rate of peptic ulcer recurrence (RPUR) and incidence of adverse reactions (IAR). Two researchers independently conducted the study selection and extracted data for included studies. The risk of bias was assessed using the Cochrane risk of bias tool. A pairwise meta-analysis was performed using RevMan V.5.3. Network meta-analysis was performed using STATA/MP V.15.0. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation. A total of 36 RCTs involving 3620 patients were included. Compared with T/Q alone, Weisu+T/Q, Weifuchun+T/Q and Puyuanhewei+T/Q had the highest CUHR, ER and <i>HP</i>ER, respectively. Weisu+T/Q and Jianweiyuyang+T/Q had the lowest RPUR and IAR, respectively. The cluster analysis results showed Jianweiyuyang+T/Q might be the best choice concerning efficacy and safety simultaneously, followed by Kangfuxin+T/Q. Among the combination therapies with the CPMs, Jianweiyuyang+T/Q might be the most favourable option for <i>H. pylori</i>-positive peptic ulcers, followed by Kangfuxin+T/Q. Considering the limited quantity and quality of the included RCTs, the results should be interpreted with caution. CRD42022327687.